tiprankstipranks

Acrivon Therapeutics price target raised to $28 from $25 at BMO Capital

BMO Capital analyst Etzer Darout raised the firm’s price target on Acrivon Therapeutics to $28 from $25 and keeps an Outperform rating on the shares. The firm is updating its model after the company provided a positive update for ACR-368 in patients with high-grade endometrial cancer, achieving a 62.5% overall response rate in patients predicted as responders using the company’s OncoSignature platform, the analyst tells investors in a research note.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue